Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Sintilimab in Advanced Gastric/GEJ Adenocarcinoma
NCT05235906Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
surufatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05235906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05235906.